CAR T-cell therapy for relapsed or refractory mantle-cell lymphoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Who cites it

3 citing papers in PubMed.

1. SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors.Cellular & molecular immunology · 2024
   Article
2. Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives.Viruses · 2021
   Review
3. Invited Review: Will Consolidation with ASCT Be a Thing of the Past for MCL and PTCL?Current hematologic malignancy reports · 2021
   Review

Corrections and comments

• Comment on
  KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as